Prasugrel better on stent-related clots than Plavix: study

0 Comments | AFP, March, 2008

CHICAGO, March 29, 2008 (AFP) — A cocktail of new anti-blood clot drug Prasugrel and aspirin reduces the risk of stent-related clots more than the standard treatment, according to a clinical trial review presented Saturday.

Prasugrel cut the risk of platelet formation around where a stent -- a small metal device -- was inserted to keep an artery open, by an average of 58 percent compared to Copidogrel (Plavix), according to analysis presented to the 57th annual American College of Cardiology conference in Chicago.

Researchers found that, during clinical trials, the anti-blood clot drug developed by US firm Elli Lilly and Japan's Daiichi Sankyo lab offered greater protection against the risk of stroke and death than Plavix, the standard treatment from American lab...